- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil, Non-Treprostinil PAH Medications
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Timeline
- 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 135
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Interventions
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Drug · Device
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Tadalafil, Placebo
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
- Conditions
- Pulmonary Hypertension
- Interventions
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Treprostinil Inhalation Solution, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Neuroblastoma
- Interventions
- 131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
- Radiation · Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled treprostinil solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- APD811, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Rotator Cuff Repair, Anterior Cruciate Ligament Reconstruction, Ankle Arthrodesis or Arthroplasty, Hallux Valgus Correction
- Interventions
- ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio), SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- San Diego, California • Bethesda, Maryland • Fort Bragg, North Carolina + 2 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
- Conditions
- Pulmonary Hypertension
- Interventions
- UT-15C SR, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 33 more
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- Oral treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Houston, Texas
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 15 more
- Conditions
- Staphylococcal Infections, Yeast Infections, Candidiasis
- Interventions
- NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID
- Biological
- Lead sponsor
- NovaDigm Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Hypertension, Pulmonary
- Interventions
- treprostinil sodium
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Healthy Adult Participants
- Interventions
- ARN-75039 oral capsules, Placebo
- Drug
- Lead sponsor
- Arisan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Pulmonary Arterial Hypertension, Renal Dysfunction
- Interventions
- UT-15C SR (treprostinil diethanolamine)
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- UNEX-42, Phosphate-buffered saline
- Biological
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 3 Days to 14 Days
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 1 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- treprostinil sodium
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
- Conditions
- Primary Refractory Neuroblastoma
- Interventions
- MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid
- Biological
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Months to 13 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Parenteral Treprostinil, Oral Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Model 10642 Implantable Intravascular Catheter
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2032
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 5 more
- Conditions
- Neuroblastoma
- Interventions
- ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Aldesleukin (IL-2), Isotretinoin
- Biological · Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Up to 8 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 10 more